{"id":390731,"date":"2018-03-13T00:00:00","date_gmt":"2018-03-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0040-2018-biopharma-rheumatoid-arthritis-treatment-algorithms-claims-data-analysis-us-2018\/"},"modified":"2026-04-30T23:44:42","modified_gmt":"2026-04-30T23:44:42","slug":"algoim0040-2018-biopharma-rheumatoid-arthritis-treatment-algorithms-claims-data-analysis-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoim0040-2018-biopharma-rheumatoid-arthritis-treatment-algorithms-claims-data-analysis-us-2018\/","title":{"rendered":"Rheumatoid Arthritis | Treatment Algorithms | Claims Data Analysis | US | 2018"},"content":{"rendered":"<p><strong>MARKET OUTLOOK <\/strong><\/p>\n<p>Treatment of rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) is typically initiated with cost-effective conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s, such as methotrexate. For\u00a0 <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients who are refractory to conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr>s, the U.S.\u00a0market is crowded with efficacious biologics, including the blockbuster tumor necrosis factor alpha (<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha) inhibitors Amgen\u2019s Enbrel, AbbVie\u2019s Humira, and Janssen\u2019s Remicade, as well as non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors such as Bristol-Myers Squibb\u2019s Orencia and Roche\/Genentech\u2019s Rituxan and Actemra. In addition, Pfizer\u2019s <abbr title=\"Janus kinase\">JAK<\/abbr> inhibitor Xeljanz, the first targeted oral treatment\u00a0for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>, has been approved for almost six years in the United States and is gaining steady uptake in early lines of therapy. The <abbr title=\"Food and Drug Administration\">FDA<\/abbr>\u2019s approval of Regeneron\/Sanofi\u2019s Kevzara in 2017 added a second <abbr title=\"interleukin\">IL<\/abbr>-6 inhibitor to the armamentarium for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>.<\/p>\n<p><strong>QUESTIONS ANSWERED <\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients?<\/li>\n<li>How have non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitor biologics and Xeljanz been integrated into the treatment algorithm?<\/li>\n<li>What proportion of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients receive drug therapy within three years of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within three years of diagnosis?<\/li>\n<li>What percentage of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with <abbr title=\"rheumatoid arthritis\">RA<\/abbr>?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390731","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390731\/revisions"}],"predecessor-version":[{"id":393855,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390731\/revisions\/393855"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}